News: Allergan Inc (AGN.N)
10 Mar 2014
Tue, Jan 14 2014
SAN FRANCISCO - A Texas judge has upheld U.S. patents covering Allergan Inc's Lumigan glaucoma drug through 2027, the company said in a regulatory filing on Tuesday, helping to send its shares up 6 percent.
SAN FRANCISCO Jan 14 - A Texas judge has upheld U.S. patents covering Allergan Inc's Lumigan glaucoma drug through 2027, the company said in a regulatory filing on Tuesday, helping to send its shares up 6 percent.
- Flexion Therapeutics Could Be Unbending To Quiet Period Expiration
- Allergan: 8 Different Insiders Have Sold Shares This Month
- Scrutiny Over Medical Device Safety Offers Opportunity For VeriTeQ
- Allergan Management Discusses Q4 2013 Results - Earnings Call Transcript
- Cramer's Lightning Round - Henry Schein Is A Stock For The Ages (1/29/14)
- Ipsen In Good Shape
- John A. Moran Eye Center’s Voyant Biotherapeutics, LLC Enters Into Exclusive R&D Collaboration Agreement with Allergan, Inc.
- Allergan Reports Fourth Quarter 2013 Operating Results
- Acceptance of NDA for Review, Acquisitions of Development Rights, Earnings Release Schedulesm and New Leaders - Research Report on Gilead, Lilly, Allergan, Incyte, and Varian Medical Systems
- Fish & Richardson Wins Patent Infringement Suit for Allergan Over Generic LUMIGAN® 0.01%
- Allergan Announces Quarterly Conference Call
- Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
- New Clinical Trials, Stock Price Movements, and Completed Acquisitions - Research Report on Merck, Lilly, Allergan, PerkinElmer, and Air Methods
- Public Offerings of Common Shares, Upcoming Events and Shareholder Meetings, and Stock Price Updates - Research Report on Zoetis, Allergan, Clovis Oncology, Isis Pharmaceuticals, and Mindray
- Divestitures, Event Participations, Patents, Clinical Studies and Trials - Research Report on Allergan, Zoetis, XOMA, Isis, and Arrowhead
- Allergan, Inc. Completes Sale of Obesity Intervention Business